Bank of America Corp /DE/ filed a Schedule 13G with the SEC on October 28, 2026, disclosing beneficial ownership of 2,205,390 shares of Q32 Bio Inc. common stock, representing 7.4% of the class, as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Bank of America Corp /DE/ reported beneficial ownership of 2,205,390 shares of Q32 Bio Inc. common stock.
  • Percent of class: The reported stake equals 7.4% of Q32 Bio Inc.'s outstanding common stock.
  • Shared voting power: Bank of America reported shared power to vote 2,204,979 shares, with sole voting power of 0.
  • Shared dispositive power: The filing lists shared dispositive power over 2,205,390 shares, with sole dispositive power of 0.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • Share count basis: The 7.4% figure is calculated against 29,769,466 outstanding shares disclosed by Q32 Bio in its quarterly report filed August 5, 2026, reflecting shares outstanding as of August 3, 2026.
  • Filing subsidiaries: The statement is filed on behalf of Bank of America Corporation and subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch Pierce Fenner & Smith, Inc.

Bank of America's Reported Position in Q32 Bio Common Stock

According to the Schedule 13G filed October 28, 2026, Bank of America Corp /DE/, incorporated in Delaware and headquartered at 100 N Tryon St, Charlotte, NC 28255, reported aggregate beneficial ownership of 2,205,390 shares of Q32 Bio Inc. common stock (CUSIP 746964105). Q32 Bio Inc. is a biotechnology company with its principal executive offices located at 830 Winter Street, Waltham, Massachusetts 02451. The filing classifies Bank of America Corp /DE/ as a parent holding company or control person under the applicable rule.

The filing covers positions held across Bank of America Corporation and three named wholly owned subsidiaries. BofA Securities, Inc. and Merrill Lynch Pierce Fenner & Smith, Inc. are each identified as broker-dealers registered under section 15 of the Securities Exchange Act, while Bank of America N.A. is identified as a bank under section 3(a)(6) of the Act. All shared voting and dispositive power figures in the filing reflect the aggregate position across these entities. The certification in the filing states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

The beneficial ownership percentage of 7.4% is based on the 29,769,466 outstanding shares that Q32 Bio Inc. disclosed in its quarterly report filed August 5, 2026, which reported share totals as of August 3, 2026. The filing was signed by Monica Yako as Authorized Signatory on behalf of Bank of America Corp /DE/ on October 28, 2026.

What Was Disclosed

Bank of America Corp /DE/ disclosed, via a Schedule 13G filed October 28, 2026, that it beneficially owns 2,205,390 shares of Q32 Bio Inc. common stock, equal to 7.4% of the outstanding class, as of the September 30, 2026 triggering event date.